Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ola Nilsson

Showing results (161-170 of 182) with videos related to

Pageof 19
Sort By:
Oncotarget|September 18, 2014
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisionsBerglind O Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2025
Growth hormone regulates the stem cell population in the growth plateNelson Tsz Long Chu, Baoyi Zhou, Jussi O Heinonen, et al.
Human Mutation|November 30, 2020
Biallelic TMEM251 variants in patients with severe skeletal dysplasia and extreme short statureNoor U Ain, Niaz Muhammad, Mehdi Dianatpour, et al.
European Journal of Pediatrics|January 23, 2016
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothersMarie Helene Schernthaner-Reiter, David Adams, Giampaolo Trivellin, et al.
European Journal of Endocrinology|January 16, 2026
Diagnostic Yield of Genetic Testing in Children with Short Stature: a Systematic ReviewRenata C Scalco, Jan W Schoones, Despoina Galetaki, et al.
The Lancet. Oncology|January 8, 2008
Gastroenteropancreatic neuroendocrine tumoursIrvin M Modlin, Kjell Oberg, Daniel C Chung, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
JCO Precision Oncology|September 11, 2020
Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown PrimaryRoger Olofsson Bagge, Akif Demir, Joakim Karlsson, et al.
Therapeutic Advances in Chronic Disease|September 9, 2022
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and descriptionMaria Luisa Brandi, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Therapeutic Advances in Chronic Disease|May 20, 2024
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysisAnnemieke M Boot, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Pageof 19

Showing results (161-170 of 182) with videos related to

Sort By:
Pageof 19
Oncotarget|September 18, 2014
Melanoma patient-derived xenografts accurately model the disease and develop fast enough to guide treatment decisionsBerglind O Einarsdottir, Roger Olofsson Bagge, Joydeep Bhadury, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 25, 2025
Growth hormone regulates the stem cell population in the growth plateNelson Tsz Long Chu, Baoyi Zhou, Jussi O Heinonen, et al.
Human Mutation|November 30, 2020
Biallelic TMEM251 variants in patients with severe skeletal dysplasia and extreme short statureNoor U Ain, Niaz Muhammad, Mehdi Dianatpour, et al.
European Journal of Pediatrics|January 23, 2016
A novel AVPR2 splice site mutation leads to partial X-linked nephrogenic diabetes insipidus in two brothersMarie Helene Schernthaner-Reiter, David Adams, Giampaolo Trivellin, et al.
European Journal of Endocrinology|January 16, 2026
Diagnostic Yield of Genetic Testing in Children with Short Stature: a Systematic ReviewRenata C Scalco, Jan W Schoones, Despoina Galetaki, et al.
The Lancet. Oncology|January 8, 2008
Gastroenteropancreatic neuroendocrine tumoursIrvin M Modlin, Kjell Oberg, Daniel C Chung, et al.
The Journal of Clinical Endocrinology and Metabolism|May 9, 2022
Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked HypophosphatemiaLeanne M Ward, Francis H Glorieux, Michael P Whyte, et al.
JCO Precision Oncology|September 11, 2020
Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown PrimaryRoger Olofsson Bagge, Akif Demir, Joakim Karlsson, et al.
Therapeutic Advances in Chronic Disease|September 9, 2022
Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and descriptionMaria Luisa Brandi, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Therapeutic Advances in Chronic Disease|May 20, 2024
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysisAnnemieke M Boot, Gema Ariceta, Signe Sparre Beck-Nielsen, et al.
Pageof 19